| Synonyms: | |
| Status: | Approved (2019) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | N07XX11 |
| UNII: | 4BC83L4PIY |
| InChI Key | NNACHAUCXXVJSP-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C17H26ClNO |
| Molecular Weight | 295.85 |
| AlogP | 4.17 |
| Hydrogen Bond Acceptor | 2.0 |
| Hydrogen Bond Donor | 0.0 |
| Number of Rotational Bond | 8.0 |
| Polar Surface Area | 12.47 |
| Molecular species | BASE |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 20.0 |
| Primary Target | |
|---|---|
| H3 receptor |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Hydrolase
|
- | 8400-8420 | - | - | 3 | |
|
Enzyme
Oxidoreductase
|
- | - | - | - | 2 | |
|
Ion channel
Voltage-gated ion channel
Potassium channels
Voltage-gated potassium channel
|
- | 1700 | - | - | - | |
|
Membrane receptor
Family A G protein-coupled receptor
Small molecule receptor (family A GPCR)
Monoamine receptor
Histamine receptor
|
2 | 12 | 6 | 0-30 | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Narcolepsy | 3 | D009290 | ClinicalTrials |
| Parkinson Disease | 3 | D010300 | ClinicalTrials |
| Narcolepsy | 3 | D009290 | ClinicalTrials |
| Prader-Willi Syndrome | 2 | D011218 | ClinicalTrials |
| Schizophrenia | 2 | D012559 | ClinicalTrials |
| Alcoholism | 2 | D000437 | ClinicalTrials |
| Kidney Diseases | 1 | D007674 | ClinicalTrials |
| Substance-Related Disorders | 1 | D019966 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 362665-56-3 |
| ChEBI | 134709 |
| ChEMBL | CHEMBL462605 |
| DrugBank | DB11642 |
| DrugCentral | 5048 |
| FDA SRS | 4BC83L4PIY |
| Guide to Pharmacology | 8924 |
| PubChem | 9948102 |
| SureChEMBL | SCHEMBL117648 |
| ZINC | ZINC000034045468 |